Nectar Lifesciences Limited
Nectar Lifesciences Limited manufactures, distributes, markets and sells pharmaceutical products in India and internationally. The company offers cephalosporins, includes pharmaceutical ingredients and intermediates comprising cefixime, cefuroxime axetil amorphous, cefuroxime axetil crystalline, cefotaxime sodium, ceftriaxone sodium, cefixime trihydrate, cefuroxime axetil, cefpodoxime proxetil an… Read more
Nectar Lifesciences Limited (NECLIFE) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.213x
Based on the latest financial reports, Nectar Lifesciences Limited (NECLIFE) has a cash flow conversion efficiency ratio of 0.213x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₹1.53 Billion) by net assets (₹7.17 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Nectar Lifesciences Limited - Cash Flow Conversion Efficiency Trend (2006–2025)
This chart illustrates how Nectar Lifesciences Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Nectar Lifesciences Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Nectar Lifesciences Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Thiogenesis Therapeutics Corp.
V:TTI
|
-0.986x |
|
ACCESS Newswire Inc.
NYSE MKT:ACCS
|
-0.019x |
|
KWANGJIN WINTEC CO. Ltd
KQ:090150
|
0.040x |
|
Pamel Yenilenebilir Elektrik Uretim AS
IS:PAMEL
|
-0.009x |
|
Samhwa Networks Co. Ltd
KQ:046390
|
0.086x |
|
Kocom Co. Ltd
KQ:015710
|
0.036x |
|
Bakrie & Brothers Tbk
JK:BNBR
|
-0.086x |
|
PT Boston Furniture Industries Tbk
JK:SOFA
|
-0.034x |
Annual Cash Flow Conversion Efficiency for Nectar Lifesciences Limited (2006–2025)
The table below shows the annual cash flow conversion efficiency of Nectar Lifesciences Limited from 2006 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | ₹9.56 Billion | ₹1.69 Billion | 0.177x | -15.67% |
| 2024-03-31 | ₹10.69 Billion | ₹2.25 Billion | 0.210x | +67.38% |
| 2023-03-31 | ₹10.65 Billion | ₹1.34 Billion | 0.126x | +43.76% |
| 2022-03-31 | ₹10.88 Billion | ₹950.05 Million | 0.087x | +333.82% |
| 2021-03-31 | ₹10.62 Billion | ₹213.79 Million | 0.020x | -91.97% |
| 2020-03-31 | ₹11.36 Billion | ₹2.85 Billion | 0.251x | +15.87% |
| 2019-03-31 | ₹11.05 Billion | ₹2.39 Billion | 0.216x | +251.66% |
| 2018-03-31 | ₹10.59 Billion | ₹651.67 Million | 0.062x | -68.82% |
| 2017-03-31 | ₹10.07 Billion | ₹1.99 Billion | 0.197x | +11.58% |
| 2016-03-31 | ₹9.54 Billion | ₹1.69 Billion | 0.177x | +17.38% |
| 2015-03-31 | ₹9.58 Billion | ₹1.44 Billion | 0.151x | -45.17% |
| 2014-03-31 | ₹9.27 Billion | ₹2.55 Billion | 0.275x | -33.90% |
| 2013-03-31 | ₹8.68 Billion | ₹3.61 Billion | 0.416x | +97.78% |
| 2012-03-31 | ₹7.84 Billion | ₹1.65 Billion | 0.210x | +246.14% |
| 2011-03-31 | ₹7.21 Billion | ₹438.09 Million | 0.061x | +142.98% |
| 2010-03-31 | ₹6.21 Billion | ₹-877.18 Million | -0.141x | -142.17% |
| 2009-03-31 | ₹3.03 Billion | ₹1.02 Billion | 0.335x | -36.23% |
| 2008-03-31 | ₹2.84 Billion | ₹1.49 Billion | 0.526x | +2777.52% |
| 2007-03-31 | ₹2.21 Billion | ₹40.34 Million | 0.018x | +110.40% |
| 2006-03-31 | ₹1.96 Billion | ₹-344.18 Million | -0.176x | -- |